Having trouble accessing articles? Reset your cache.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 11/18 cls
Alimera Sciences Inc. (NASDAQ:ALIM) Cowen Simos Simeonidis Downgrade Neutral (from market outperform) $1.29 -34%
Simeonidis downgraded after FDA issued a second complete response for an NDA for Alimera's Iluvien to treat diabetic macular edema (DME) associated with diabetic retinopathy. According to Alimera, FDA said the "significant" risks of adverse events in the Phase III

Read the full 819 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE